A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).

Authors: Alexander Z Wei, Basil Bakir, Andrew T Lenis, Christopher B. Anderson, Karie Runcie, Guarionex Joel DeCastro, Samuel S Pan, Michael M Shen, James M. McKiernan, Mark N. Stein

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.tps882

Source: Full article

---

Abstract

TPS882